* Champions Oncology Inc CSBR.OQ CSBR.O is expected to show
a rise in quarterly revenue when it reports results on June 29
(estimated) .
* The Baltimore, Maryland-based company is expected to report
a 14.6% increase in revenue to $10.03 million from $8.75
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Champions Oncology Inc
is for breakeven results per share. For the same quarter last
year, the company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Champions
Oncology Inc is $15, about 32.6% above its last closing price
of $10.11.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jan. 31 2021 0.00 0.01 0.05 Beat 649.6
Oct. 31 2020 0.00 0.00 0.00 Met
Jul. 31 2020 0.02 0.02 0.01 Missed -50
Apr. 30 2020 0.02 -0.14 Missed -1,033
.3
Jan. 0.03 0.03 0.03 Met 12.5
31 2020
Oct. 31 2019 -0.02 0.01 0.02 Beat 166.7
Jul. 31 2019 0.04 0.04 -0.05 Missed -225
Apr. 30 2019 0.03 -0.01 Missed -133.3
This summary was machine generated June 30 at 02:51 GMT. All
figures in US dollars unless otherwise stated